文献速递血栓与止血

将IgG降解酶锚定于血小板表面选择性中和抗血小板抗体

Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies.
PubMed 文献 · Blood Adv · 2022-01-01

本研究构建了将IgG降解酶IdeS靶向血小板表面FcγRIIA的重组蛋白偶联物scIV.3-IdeS。体外实验显示该偶联物可减少免疫性血小板减少症(ITP)患者抗血小板IgG与血小板的结合及血小板吞噬,且不降低正常IgG;在表达人FcγRIIA的小鼠ITP模型中,scIV.3-IdeS减轻血小板减少并显著改善输注血小板的半衰期。作者认为其可能成为ITP伴严重出血患者的潜在治疗。

要点

  • scIV.3-IdeS将IdeS靶向血小板表面FcγRIIA,选择性清除致病性抗血小板IgG。
  • 体外可减少ITP患者抗血小板IgG结合及血小板吞噬,不降低正常IgG。
  • 在表达人FcγRIIA的小鼠ITP模型中减轻血小板减少并改善输注血小板半衰期。

核心结论

  • scIV.3-IdeS可选择性清除致病性抗血小板IgG,作者认为其可能成为ITP伴严重出血患者的潜在治疗。

研究设计与样本

  • 研究构建了将FcγRIIA抗体克隆IV.3的单链可变片段C端与IdeS N端定点连接的重组蛋白偶联物scIV.3-IdeS。
  • 体外评价scIV.3-IdeS处理血小板后ITP患者抗血小板IgG结合及血小板吞噬,并检测正常IgG水平。
  • 在表达人FcγRIIA的小鼠ITP模型中评价scIV.3-IdeS对血小板减少及输注血小板半衰期的影响。

主要发现

  • scIV.3-IdeS处理的血小板与ITP患者抗血小板IgG结合减少,体外血小板吞噬减少,正常IgG未见降低。
  • 表达人FcγRIIA的小鼠ITP模型中,scIV.3-IdeS减轻血小板减少。
  • 表达人FcγRIIA的小鼠中,scIV.3-IdeS显著改善输注血小板的半衰期。

临床怎么用

  • 作者认为scIV.3-IdeS可能成为ITP伴严重出血患者的潜在治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by immunoglobulin G (IgG)-mediated platelet destruction. Current therapies primarily focus on reducing antiplatelet antibodies using immunosuppression or increasing platelet production with thrombopoietin mimetics. However, there are no universally safe and effective treatments for patients presenting with severe life-threatening bleeding. The IgG-degrading enzyme of Streptococcus pyogenes (IdeS), a protease with strict specificity for IgG, prevents IgG-driven immune disorders in murine models, including ITP. In clinical trials, IdeS prevented IgG-mediated kidney transplant rejection; however, the concentration of IdeS used to remove pathogenic antibodies causes profound hypogammaglobulinemia, and IdeS is immunogenic, which limits its use. Therefore, this study sought to determine whether targeting IdeS to FcγRIIA, a low-affinity IgG receptor on the surface of platelets, neutrophils, and monocytes, would be a viable strategy to decrease the pathogenesis of antiplatelet IgG and reduce treatment-related complications of nontargeted IdeS. We generated a recombinant protein conjugate by site-specifically linking the C-terminus of a single-chain variable fragment from an FcγRIIA antibody, clone IV.3, to the N-terminus of IdeS (scIV.3-IdeS). Platelets treated with scIV.3-IdeS had reduced binding of antiplatelet IgG from patients with ITP and decreased platelet phagocytosis in vitro, with no decrease in normal IgG. Treatment of mice expressing human FcγRIIA with scIV.3-IdeS reduced thrombocytopenia in a model of ITP and significantly improved the half-life of transfused platelets expressing human FcγRIIA. Together, these data suggest that scIV.3-IdeS can selectively remove pathogenic antiplatelet IgG and may be a potential treatment for patients with ITP and severe bleeding.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lynch DR, Stringham EN, Zhang B, et al. Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies. Blood Adv. 2022. PMID: 35737875. doi:10.1182/bloodadvances.2022007195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。